drugset
drugset / Trial / NCT06790862

A Trial of SHR0302Base in Patients With Vitiligo

NCT06790862 ↗

Phase 2 Active not recruiting 155 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of SHR0302Base in participants with nonsegmental vitiligo.

Timeline

Start
2025-02-13
Primary completion
2026-03-03
Completion
2026-04

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR0302Base Unknown — —

Indications

vitiligo